Sarepta Therapeutics, Inc. focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare diseases. The company offers EXONDYS 51, a disease-modifying therapy for duchenne muscular dystrophy (DMD). Its products pipeline include Golodirsen, a product candidate that binds to exon 53 of dystrophin pre-mRNA, which results in exclusion or skipping of exon during mRNA processing in patients with genetic mutations; and Casimersen, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the DMD gene. In addition, the company's pipeline comprise SRP-5051, a peptide conjugated PMO that binds to exon 51 of dystrophin pre-mRNA. It has collaboration agreements with Nationwide Children's Hospital to advance micro-dystrophin gene therapy program under the research and license option agreement; Galgt2, a gene therapy program for the treatment of DMD; and Neutrophin 3, a gene therapy program to treat Charcot-Marie-Tooth neuropathies. The company also has a license agreement with Lysogene to develop LYS-SAF302, a gene therapy for mucopolysaccharidosis IIIA; a license and option agreement with Lacerta to develop treatments for CNS-targeted and lysosomal storage diseases; and research collaboration and option agreement with Genethon to develop micro-dystrophin gene therapy products. In addition, it has a research agreement with Duke University to advance gene editing CRISPR/Cas9 technology for restoring dystrophin expression; a collaboration agreement with Summit (Oxford) Ltd. to commercialize products in Summit's utrophin modulator pipeline; a strategic collaboration with Paragon Bioservices; and a strategic collaboration with CENTOGENE for the identification of patients with DMD in the Middle East and North Africa region. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts.

Outperform Votes

Underperform Votes

Community Sentiment

Sarepta Therapeutics has received 62.95% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Sarepta Therapeutics and other stocks. Vote “Outperform” if you believe SRPT will outperform the S&P 500 over the long term. Vote “Underperform” if you believe SRPT will underperform the S&P 500 over the long term. You may vote once every thirty days.

1.0 Company Ownership

In the past three months, Sarepta Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,991,000.00 in company stock.

Miscellaneous

Receive SRPT News and Ratings via Email

Sign-up to receive the latest news and ratings for SRPT and its competitors with MarketBeat's FREE daily newsletter.

Sarepta Therapeutics (NASDAQ:SRPT) Frequently Asked Questions

How has Sarepta Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Sarepta Therapeutics' stock was trading at $102.8150 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, SRPT shares have increased by 43.9% and is now trading at $147.99. View which stocks have been most impacted by Coronavirus.

24 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sarepta Therapeutics in the last year. There are currently 1 hold rating and 23 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Sarepta Therapeutics.

When is Sarepta Therapeutics' next earnings date?

How were Sarepta Therapeutics' earnings last quarter?

Sarepta Therapeutics Inc (NASDAQ:SRPT) announced its earnings results on Wednesday, May, 6th. The biotechnology company reported ($0.23) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($2.17) by $1.94. The biotechnology company earned $113.67 million during the quarter, compared to analyst estimates of $118.18 million. Sarepta Therapeutics had a negative net margin of 160.96% and a negative return on equity of 64.67%. The firm's revenue for the quarter was up 30.6% compared to the same quarter last year. During the same period last year, the business earned ($1.07) EPS. View Sarepta Therapeutics' earnings history.

What price target have analysts set for SRPT?

24 brokers have issued twelve-month price targets for Sarepta Therapeutics' shares. Their forecasts range from $160.00 to $260.00. On average, they anticipate Sarepta Therapeutics' share price to reach $197.86 in the next year. This suggests a possible upside of 33.7% from the stock's current price. View analysts' price targets for Sarepta Therapeutics.

What are Wall Street analysts saying about Sarepta Therapeutics stock?

Here are some recent quotes from research analysts about Sarepta Therapeutics stock:

1. According to Zacks Investment Research, "Sarepta's DMD drug, Exondys 51, posted impressive growth in 2019. Sarepta is focused on reimbursement programs for better accessibility of the drug. The company continues to make progress with its DMD pipeline. The approval to Vyondys 53 in December 2019 is likely to boost the company’s prospects as it will increase the eligible DMD patient population. However, dependence on a single product, Exondys 51, remains a concern. The company is yet to gain approval for Exondys 51 in the EU. The company has also faced other pipeline and regulatory setbacks. Moreover, the DMD market is getting competitive as several other companies are developing therapies. Estimates movement have been mixed ahead of Q1 earnings. The company has a mixed record of earnings surprises in the recent quarters." (5/2/2020)

2. Evercore ISI analysts commented, "We intend in connection with our next trial or set of trials associated with commercial material to address those issues and won’t move some of the restrictions that out of an overabundance or an abundance of caution exists within the protocol for what we call [indiscernible] (55:07) and now Study 102. So that our ultimate goal is to have the broadest possible coverage both of patients, age groups, geography but also genotype as well." (8/8/2019)

Has Sarepta Therapeutics been receiving favorable news coverage?

News stories about SRPT stock have trended somewhat negative this week, InfoTrie reports. InfoTrie scores the sentiment of media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Sarepta Therapeutics earned a media sentiment score of -1.1 on InfoTrie's scale. They also gave news coverage about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the company's share price in the near future. View the latest news aboutSarepta Therapeutics.

How do I buy shares of Sarepta Therapeutics?

Shares of SRPT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Sarepta Therapeutics' stock price today?

One share of SRPT stock can currently be purchased for approximately $147.99.

How big of a company is Sarepta Therapeutics?

Sarepta Therapeutics has a market capitalization of $11.54 billion and generates $380.83 million in revenue each year. The biotechnology company earns $-715,080,000.00 in net income (profit) each year or ($9.71) on an earnings per share basis. Sarepta Therapeutics employs 499 workers across the globe.